Combined >800 academic publications and >120 years of experience in clinical research, drug development, and clinical technologies.
Eirini Schlosser, MSc
CEO & Co-Founder
Eirini Schlosser is a serial entrepreneur with experience building and leading data science and A.I. applications. After executing on > $60 Billion deal value in technology, healthcare, and consumer transactions as a member of Morgan Stanley’s Mergers & Acquisitions Execution Team, Eirini successfully transitioned from finance to technology where she spent the last 7 years developing, coding, and designing technologies as well as advising and investing other start-ups. She holds professional certifications in machine learning from MIT and a Masters from London Business School.
” I co-founded Dyania Health with the vision to be what the name means: Genius. Genius means we focus on the future. The future of healthcare is defined by new therapeutic innovations and how we get those innovations to the right patients, with specific conditions, for the best patient outcomes. Building a health genius requires us to extract sparks of knowledge and experience from each expert on our team and connect the dots to engineer solutions to big medical problems. I’m excited that we have the opportunity every day to play an integral role in the process to bring new therapeutics to patients with life threatening diseases. “
Dimitrios Iliopoulos, PhD, MBA
Senior Scientific Advisory
Dr. Iliopoulos was Assistant Professor of Microbiology & Immunology at Harvard Medical School, Associate Professor of Medicine at UCLA David Geffen School of Medicine and Founder/Director of the UCLA Center for Systems Biomedicine. Leads biomedical data research efforts in Dyania Health for different human diseases, including autoimmune and infectious diseases. He is an expert on identification and development of novel therapeutics using artificial intelligence methods. He has an extensive publication record and awards related to the pathobiology and development of therapeutics for inflammatory diseases. MIT certified on artificial intelligence.
Chief Technology Officer
Konstantine has been in the AI space for more than 10 years, as an academic, a senior research scientist, an engineer, a team leader, a manager of managers, and a senior executive. He has also advised and worked with a number of startups throughout his career. Before Dyania, Konstantine was a senior science manager at Amazon, where his teams built and deployed deep-learning models for advanced NLU (Natural Language Understanding) for Alexa. Prior to Alexa AI, he was a team leader at Bloomberg AI, where he grew a team that worked on NLP-powered search and knowledge graphs. He holds a PhD in Computer Science from MIT’s AI Lab and has authored over 50 peer-reviewed publications, several book chapters, and a textbook, in fields ranging from NLP and AI to programming languages, formal methods, and cognitive science.
Director of Product
Julie leads product management at Dyania Health and has been in the technology space for almost a decade, primarily in another health tech vertical focused on health insurance. She brings a proven record of launching products focused on delivering value to the customer while navigating the highly regulated insurance industry as it relates to data privacy and security, user access control, auditability, and multi-layered customer relationships. As Julie began to look for adjacent challenges in other health tech verticals, Dyania stood out as an opportunity to make a huge impact by helping to give patients quicker access to life saving drugs.
Alexandra Drakaki, MD PhD
Senior Medical Director
Dr. Drakaki is an Assistant Professor of Hematology/Oncology and Urology, Medical Director of the Genitourinary Oncology Program and co-Director of Clinical Trial Research at the Institute of Urologic Oncology at UCLA. She is an expert on designing and running oncology clinical trials. She performed her hematology/oncology fellowship at Beth Israel Deaconess Medical Center at Harvard Medical School and her residency in internal medicine at Tufts University.
Dr Drakaki is the Principal investigator on multiple phase I-III clinical research studies for genitourinary cancers.Leading an innovative phase I study treating patients who have metastatic renal cell carcinoma with autologous dendritic cells transduced with AdGMCA9 (Kite Pharma, a Gilead Company).
Allan J. Pantuck, MD
Senior Medical Director
Chair of the UCLA IRB Committee and thought leader in the field of cancer immunotherapy and co-founder of Kite Pharma. Expert in clinical trial design and involved in the keynote study showing efficacy of sunitinib (Pfizer) in patients with renal cell carcinoma.
Extensive experience on clinical trials design, performance and regulatory affairs. Allan is the executive chair of the UCLA IRB Committee, Professor of Urology at the David Geffen School of Medicine at UCLA and Vice Chair of Academic Affairs for the Department of Urology, Executive Chair of the UCLA IRB, a member of the Executive Committee of the Institute of Urologic Oncology. Allan performed his urology/oncology fellowship at UCLA School of Medicine and holds an MD degree from Robert Wood Johnson Medical School.
Athanasios Papatsoris, MD PhD
Senior Medical Director
Professor Athanasios Papatsoris holds two MSc and PhD with a 2-year Endourology/Laparoscopy fellowship in London and Le Mans. He has an honorary contract with Addenbrooke’s Hospital, Cambridge and he is a faculty member of Cambridge Medical Academy. He is the v. Chairman of the EBU Examination Committee. He is Professor of Urology of the National and Kapodistrian University of Athens at the 2nd University Department of Urology, Sismanoglio. General Hospital, Athens Greece.
He is on the Board of HUA, IMBE and HGUCG. His H-Index is 38 with more than 203 publications in PubMed and with more than 4100 citations. Recently he received the “Arthur Smith” award.
Petros Grivas, MD PhD
Senior Oncology Advisor
World expert on clinical trial design and performance of bladder cancer phase I-III clinical trials.Identified that avelumab (Pfizer, Merck KGaA) plus best supportive care significantly prolonged overall survival among patients with urothelial cancer.Dr. Petros Grivas is board-certified medical oncologist with expertise in genitourinary (GU) cancers. He is the Clinical Director of the GU cancers Program at University of Washington and Associate Professor (Dept of Medicine, Division of Oncology). He received M.D. and Ph.D. in Greece in 2005 and 2009, respectively. He completed Internal Medicine Residency at Hahnemann University Hospital/Drexel University College of Medicine (Philadelphia) in 2010, and Hematology/Oncology Fellowship at University of Michigan (Ann Arbor) in 2013. He was Clinical Lecturer before he was recruited as Assistant Professor at Cleveland Clinic (Cleveland). He had main role in clinical trials leading to FDA approval of new drugs for bladder/urothelial cancer.
Panos Zoubourlis, MD
Clinical Research Associate
Panos Zoubourlis finished his medical degree at the National and Kapodistrian University of Athens with high honors and a GPA of 8.7/10. He proceeded to score above the 95th percentile on the USMLE Step 1 Boards and completed a clinical elective program at John Hopkins Medical School in the hematology oncology department. He has been published as primary author on the research article titled ”Systemic Therapies for the Management of Non-Clear Cell Renal Cell Carcinoma: What Works, What Doesn’t, and What the Future Holds” and has been subsequent author in 4 other publications focused on the fields of oncology, gynecology, and cardiology. Panos brings a mathematical approach to clinical technology applications, which allows the team to build computational models around clinical characteristics. He uniquely combines skills in coding with medical knowledge to bridge multidisciplinary teams that come from pure engineering and clinician backgrounds. As such, he has made himself an invaluable pillar to the growth and implementation of Dyania Health’s vision.
Helaine Catalano, CPC, ACC
Executive Advisory & Human Resources
Helaine Catalano brings 30 years of experience as a Human Resource Executive, providing organizational leadership coaching and development to accelerate performance and productivity of individuals and teams. A former Executive of Johnson & Johnson, she was most recently Vice President of Human Resources, Global Franchises and Functions for the Consumer Products Company. She was instrumental in driving employee engagement programs for high performance work environments.
Dino Zaharopoulos, MBA
Director of Finance
Dino has 20+ years of experience in sales, finance, and accounting. He has worked for both Fortune 500 and start-up companies in various finance and accounting roles, while also maintaining key relationships with top 10 CRO’s. Dino holds an MBA from USC with a concentration in Finance.
Zacharoula Economou, MSc
Chief of Staff
Director of Product & Marketing Design
Konstantinos studied Art & Design at University of Sunderland, Great Britain specialising in Graphic Design. For the past 15 years he has continuously worked as a freelance designer on numerous design projects. His focus is on the design of web sites, Branding Identities and UI/UX Design.